查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
移植免疫抑製剂市场 - 预测 2023-2028
市场调查报告书
商品编码
1295386

移植免疫抑製剂市场 - 预测 2023-2028

Transplant Immunosuppressive Drug Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 113 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

移植免疫抑製剂市场预计将从2021年的90.96亿美元增至2028年的145.1亿美元，预测期内復合年增长率为6.90%。

移植技术的最新进展，包括微创手术和改进的移植后护理，提高了器官移植的成功率。因此，对移植免疫抑製剂的需求不断增长，以维持移植器官的活力并防止排斥反应。

这些药物有助于保护患者免受移植的外来器官的排斥。此外，心血管疾病、糖尿病、癌症和哮喘等慢性病患病率的上升预计将增加对器官移植的需求，从而在预测期内进一步推动移植免疫抑製剂市场的发展。

药物研究和开发的重大进展导致了新型和改进的移植免疫抑製剂的推出。这些药物旨在提高疗效、最大限度地减少副作用并改善患者的治疗结果，从而推动市场增长。此外，老龄化社会更容易出现器官衰竭和慢性疾病，增加了对器官移植的需求。随着全球老年人口的增加，移植免疫抑製剂市场预计将进一步扩大。

推动市场增长的主要原因之一是器官移植手术数量的增加。

据卫生资源和服务管理局称，2022 年将进行超过 42,000 例移植手术，其中包括 25,499 例肾臟、9,528 例肝臟、108 例胰腺、4,111 例心臟和 2,692 例其他移植。

外科技术的进步提高了器官移植手术的成功率，使其成为一种更安全、更可行的治疗方法。微创手术、腹腔镜技术以及活体移植和配对器官交换计划等创新移植方法正在扩大可用器官库并增加手术数量。此外，政府、医疗保健组织和非营利组织还建立了专门的计划和网络来促进和便利器官移植。这些举措的重点是建立有效的器官分配系统、改善移植基础设施以及提高器官捐赠的意识。例如，美国器官移植网络（UNOS）帮助管理器官移植系统并协调器官分配。

器官移植领域预计将占据较大的市场份额。

移植免疫抑製剂市场按移植类型分为组织移植和器官移植。根据卫生资源和服务管理局 2023 年 1 月收集的数据，共有 25,499 例肾臟移植手术，而肝臟移植手术为 9,528 例，心臟移植手术为 4,111 例，肺移植手术为 2,692 例。图中的其他移植物包括同种异体移植物，例如面部、手部和腹壁。

从地区来看，移植免疫抑製剂市场分为北美、南美、欧洲、中东和非洲以及亚太地区。组织工程市场的发展、医疗成本的上升以及器官移植手术的增加正在推动北美移植免疫抑製剂市场的增长。

根据联合国器官共享网络（UNOS）提供的数据显示，2022年美国进行的器官移植手术总数为42,887例，比2021年的手术数量增长了3.7%。此外，根据同一消息来源，2022年进行了25,498例肾移植手术，比2021年增加了3.4%。器官移植手术的增加将对美国移植免疫抑製剂的需求产生积极影响，加速市场增长。

市场趋势：

  • 2021 年 7 月，美国食品和药物管理局批准 Astella Inc. 的 PROGRAF(R) 用于在美国接受肺、肝、肾和心臟移植的患者。同样在 2020 年 12 月，美国参议院通过了一项免疫抑製剂法案，扩大了肾移植受者的医疗保险覆盖范围。通过延长医疗保险，患者将可以获得所有救生药物。
  • 2022年8月，印度Concord Biotech Limited向市场监管机构印度证券交易委员会（SEBI）提交了一份DRHP（Draft Red Herring Prospectus），拟通过首次公开募股（IPO）筹集资金。
  • 2022年9月，Strides的环孢素软胶囊获得美国FDA批准。随着他克莫司胶囊、环孢素软胶囊以及吗替麦考酚酯片剂和胶囊添加到其针对美国市场的免疫抑製剂产品组合中，Strides 进一步巩固了其在市场上的地位。
  • 2022年9月，中东和非洲开罗与外国公司合作开设器官移植中心。该器官移植设施包括移植物、患者和捐赠者的自动化数据库。
  • 2022年9月，卡纳塔克邦国家器官和组织移植组织（SOTTO）获得印度中央政府的正式批准，以促进该地区的器官捐献。该计划已批准 840 万印度卢比（101,000 美元）的预算。

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场细分
  • 货币
  • 先决条件
  • 基准年和预测年的时间表

第二章研究方法论

  • 调查设计
  • 调查数据
  • 确认

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动力
  • 市场製约因素
  • 波特五力分析
  • 行业价值链分析
  • 产品管线

第五章移植免疫抑製剂市场：按类型

  • 介绍
  • 入门药
  • 保养药

第六章移植免疫抑製剂市场：按移植类型分类

  • 介绍
  • 组织移植
  • 器官移植

7.按地区划分的移植免疫抑製剂市场

  • 介绍
  • 北美
    • 按类型
    • 按移植类型
    • 按国家
  • 南美洲
    • 按类型
    • 按移植类型
    • 按国家
  • 欧洲
    • 按类型
    • 按移植类型
    • 按国家
  • 中东/非洲
    • 按类型
    • 按移植类型
    • 按国家
  • 亚太地区
    • 按类型
    • 按移植类型
    • 按国家

第八章竞争格局与分析

  • 主要公司及战略分析
  • 初创企业和市场盈利能力
  • 合併、收购、协议与合作
  • 供应商竞争力矩阵

第九章公司简介

  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Sanofi Genzyme
  • Novartis Pharmaceuticals Corporation
  • Mylan N.V.
  • Hoffmann-La Roche Ltd
简介目录
Product Code: KSI061612968

The transplant immunosuppressive drugs market is expected to grow at a compound annual growth rate of 6.90% over the forecast period, reaching US$14.510 billion in 2028 from US$9.096 billion in 2021.

The market in recent times has been witnessing advancements in transplantation techniques, including minimally invasive procedures and improved post-transplant care, which have increased the success rates of organ transplants. This has led to a higher demand for transplant immunosuppressive drugs to maintain the viability of transplanted organs and prevent rejection.

These drugs help protect patients against rejection of the transplanted foreign organ by their bodies. Moreover, the rising prevalence of chronic diseases such as cardiovascular disease, diabetes, cancer, and asthma is expected to increase the demand for organ transplants, further boosting the transplant immunosuppressive drugs market during the forecast period.

Significant advancements in pharmaceutical research and development have led to the introduction of new and improved transplant immunosuppressive drugs. These drugs are designed to enhance efficacy, minimize side effects, and improve patient outcomes, driving market growth. Moreover, the aging population is more prone to organ failure and chronic diseases, leading to a higher demand for organ transplantation. As the geriatric population grows globally, the transplant immunosuppressive drugs market is expected to expand further.

One of the primary reasons driving the market's growth is the increased number of organ transplant surgeries.

According to the health resources and services administration, 42,000+ transplants were performed in 2022, out of which 25,499 were for kidneys, 9,528 were for the liver, 108 were for the pancreas, 4,111 were for the heart, and 2,692 were for others.

Advancements in surgical techniques have improved the success rates of organ transplant surgeries, making them safer and more viable treatment options. Minimally invasive procedures, laparoscopic techniques, and innovative transplant approaches, such as living donor transplants and paired organ exchange programs, have expanded the pool of available organs and increased the number of surgeries performed. Furthermore, governments, healthcare organizations, and non-profit organizations have established dedicated programs and networks to promote and facilitate organ transplantation. These initiatives focus on creating efficient organ allocation systems, improving transplantation infrastructure, and increasing awareness about organ donation. For example, the United Network for Organ Sharing (UNOS) in the United States manages the organ transplant system and helps coordinate the allocation of organs.

The organ transplantation segment will constitute a significant market share.

The transplant immunosuppressive drug market is segmented by transplant type into tissue and organ transplantation. According to the data collected by health resources and service administration on January 2023, there were 25,499 kidney transplants, whereas 9,528 liver transplants and heart and lung transplants were 4,111 and 2,692, respectively. Other transplants in the graph include allograft transplants like the face, hands, and abdominal wall.

The transplant immunosuppressive drugs market, by geography, is analyzed into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The development in tissue engineering and growing expenditure on healthcare, coupled with the increase in organ transplant surgeries, are driving the market growth for transplant immunosuppressive drugs in North America.

According to the data provided by the United Network for Organ Sharing (UNOS), in 2022, the total number of organ transplant procedures performed in the USA stood at 42,887, which signified an increase of 3.7% in comparison to the number of procedures performed in 2021. Moreover, as per the same source, 25,498 kidney transplant procedures were performed in 2022, representing a 3.4% increase over 2021. Such an increase in organ transplant procedures will positively impact the demand for transplant immunosuppressive drugs in the USA, accelerating market growth.

Market Developments:

  • In July 2021, the U.S. Food and Drug Administration approved Astella Inc's "PROGRAF®," which would be used in the U.S. for people undergoing lung, liver, kidney, and heart transplants. Also, in December 2020, the U.S. Senate passed immunosuppressive drug legislation to extend Medicare coverage for patients who had undergone kidney transplants. Extended Medicare would enable patients to have access to all the lifesaving medications.
  • In August 2022, the India-based Concord Biotech Limited, one of the market share leaders in the development and production of specific fermentation-based APIs for immunosuppressants and oncology, filed its Draught Red Herring Prospectus (DRHP) with the markets regulator Securities and Exchange Board of India (SEBI) to raise money through an initial public offering (IPO).
  • In September 2022, Strides' Cyclosporine Softgel Capsules were given USFDA clearance. With the addition of Tacrolimus capsules, Cyclosporine Softgel capsules, and Mycophenolate Mofetil tablets and capsules to its range of immunosuppressant products for the U.S. market, Strides further solidified its position in the market.
  • In September 2022, Cairo in the Middle East and Africa opened an organ transplant center in collaboration with foreign businesses. This organ transplant facility includes an automated database for transplants, patients, and donors.
  • In September 2022, the State Organ Tissue Transplant Organisation (SOTTO) of Karnataka received official recognition from the Indian government's central office to promote organ donation in the region. A budget of INR 84 lakh (USD 101,000) was approved for the program.

Market Segmentation:

By Type

  • Induction Drugs
  • Maintenance Drugs

By Transplant Type

  • Tissue Transplantation
  • Organ Transplantation

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Data
  • 2.3. Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Product Pipeline

5. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Induction Drugs
  • 5.3. Maintenance Drugs

6. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TRANSPLANT TYPE

  • 6.1. Introduction
  • 6.2. Tissue Transplantation
  • 6.3. Organ Transplantation

7. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Type
    • 7.2.2. By Transplant Type
    • 7.2.3. By Country
    • 7.2.3.1. United States
    • 7.2.3.2. Canada
    • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Type
    • 7.3.2. By Transplant Type
    • 7.3.3. By Country
    • 7.3.3.1. Brazil
    • 7.3.3.2. Argentina
    • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Type
    • 7.4.2. By Transplant Type
    • 7.4.3. By Country
    • 7.4.3.1. UK
    • 7.4.3.2. Germany
    • 7.4.3.3. France
    • 7.4.3.4. Italy
    • 7.4.3.5. Spain
    • 7.4.3.6. Others
  • 7.5. Middle East and Africa (MEA)
    • 7.5.1. By Type
    • 7.5.2. By Transplant Type
    • 7.5.3. By Country
    • 7.5.3.1. Saudi Arabia
    • 7.5.3.2. UAE
    • 7.5.3.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Type
    • 7.6.2. By Transplant Type
    • 7.6.3. By Country
    • 7.6.3.1. China
    • 7.6.3.2. Japan
    • 7.6.3.3. South Korea
    • 7.6.3.4. India
    • 7.6.3.5. Indonesia
    • 7.6.3.6. Thailand
    • 7.6.3.7. Taiwan
    • 7.6.3.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Astellas Pharma Inc.
  • 9.2. Bristol-Myers Squibb Company
  • 9.3. Sanofi Genzyme
  • 9.4. Novartis Pharmaceuticals Corporation
  • 9.5. Mylan N.V.
  • 9.6. Hoffmann-La Roche Ltd